SCN1A as a Therapeutic Target for Dravet Syndrome.

1.1 via antisense oligonucleotides or virus-borne vectors is the most promising avenue for meaningful improvement in Dravet syndrome treatment, with the potential to not only reduce seizures but also address the multiple co-morbidities associated with this disease. However, human clinical trial data are necessary determine safety and to clarify if, and to what extent, these interventions modify the natural history of Dravet syndrome.